Topical imidazoquinoline therapy of cutaneous squamous cell carcinoma polarizes lymphoid and monocyte/macrophage populations to a Th1 and M1 cytokine pattern - PubMed (original) (raw)
Topical imidazoquinoline therapy of cutaneous squamous cell carcinoma polarizes lymphoid and monocyte/macrophage populations to a Th1 and M1 cytokine pattern
K J Smith et al. Clin Exp Dermatol. 2004 Sep.
Abstract
Imidazoquinolines are topical immune response modifiers. Imiquimod (IMI), the first imidazoquinoline, is approved for the treatment of genital human papillomavirus disease and has shown success as a therapeutic agent for cutaneous premalignant and malignant tumours. To define the pattern of polarization of the local immune response to invasive cutaneous squamous cell carcinoma (SCC) we pretreated 10 SCCs that were > 3 cm in diameter for 2 weeks with IMI. The tumours were treated on Monday, Wednesday and Friday and excised the next Monday. A battery of immunohistochemical markers was used to define the mononuclear cell populations in the diagnostic, and the excisional biopsy specimens. The total inflammatory infiltrate was increased after IMI therapy: the greatest increase was in the CD8 T cells with a marked relative decrease in the CD68 monocytic/macrophages; the majority of the CD8 T cells showed expression of cytotoxic granules, T cell-restricted intracellular antigen (TIA) and granzyme B. The relative numbers of monocytes/macrophages were decreased after therapy with IMI with a decrease in CD68+, CD23+, and CD14+ cells and an increase in MAC-397+, and factor XIIIa+ cells. The epidermal dendritic cells showed a > 75% decrease in CD1a+ cells. The immunohistochemical marker profile after IMI therapy is consistent with that induced by a Th1 and M1 cytokine polarization pattern. This cytokine pattern is known to be more effective in defence against tumours as well as viral infections.
Similar articles
- Characterization of the cellular infiltrate during successful topical treatment of lentigo maligna with imiquimod.
Michalopoulos P, Yawalkar N, Brönnimann M, Kappeler A, Braathen LR. Michalopoulos P, et al. Br J Dermatol. 2004 Oct;151(4):903-6. doi: 10.1111/j.1365-2133.2004.06176.x. Br J Dermatol. 2004. PMID: 15491436 - In vivo characterization of the inflammatory infiltrate and apoptotic status in imiquimod-treated basal cell carcinoma.
De Giorgi V, Salvini C, Chiarugi A, Paglierani M, Maio V, Nicoletti P, Santucci M, Carli P, Massi D. De Giorgi V, et al. Int J Dermatol. 2009 Mar;48(3):312-21. doi: 10.1111/j.1365-4632.2009.03916.x. Int J Dermatol. 2009. PMID: 19261026 Clinical Trial. - The imidazoquinolines and their place in the therapy of cutaneous disease.
Smith KJ, Hamza S, Skelton H. Smith KJ, et al. Expert Opin Pharmacother. 2003 Jul;4(7):1105-19. doi: 10.1517/14656566.4.7.1105. Expert Opin Pharmacother. 2003. PMID: 12831337 Review. - Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma.
Vidal D, Matías-Guiu X, Alomar A. Vidal D, et al. Clin Exp Dermatol. 2004 Sep;29(5):518-25. doi: 10.1111/j.1365-2230.2004.01601.x. Clin Exp Dermatol. 2004. PMID: 15347339 Clinical Trial. - The treatment of viral infections and nonmelanoma skin cancers.
Del Rosso JQ. Del Rosso JQ. Cutis. 2007 Apr;79(4 Suppl):29-35. Cutis. 2007. PMID: 17508493 Review.
Cited by
- Toll-like receptor 4 in pancreatic damage and immune infiltration in acute pancreatitis.
Mattke J, Darden CM, Lawrence MC, Kuncha J, Shah YA, Kane RR, Naziruddin B. Mattke J, et al. Front Immunol. 2024 Mar 22;15:1362727. doi: 10.3389/fimmu.2024.1362727. eCollection 2024. Front Immunol. 2024. PMID: 38585277 Free PMC article. Review. - Local Chemotherapy as an Adjuvant Treatment in Unresectable Squamous Cell Carcinoma: What Do We Know So Far?
Bennardo L, Bennardo F, Giudice A, Passante M, Dastoli S, Morrone P, Provenzano E, Patruno C, Nisticò SP. Bennardo L, et al. Curr Oncol. 2021 Jun 23;28(4):2317-2325. doi: 10.3390/curroncol28040213. Curr Oncol. 2021. PMID: 34201867 Free PMC article. Review. - Case Report: Combined Intra-Lesional IL-2 and Topical Imiquimod Safely and Effectively Clears Multi-Focal, High Grade Cutaneous Squamous Cell Cancer in a Combined Liver and Kidney Transplant Patient.
Vidovic D, Simms GA, Pasternak S, Walsh M, Peltekian K, Stein J, Helyer LK, Giacomantonio CA. Vidovic D, et al. Front Immunol. 2021 May 27;12:678028. doi: 10.3389/fimmu.2021.678028. eCollection 2021. Front Immunol. 2021. PMID: 34122442 Free PMC article. Review. - Targeted Repolarization of Tumor-Associated Macrophages via Imidazoquinoline-Linked Nanobodies.
Bolli E, Scherger M, Arnouk SM, Pombo Antunes AR, Straßburger D, Urschbach M, Stickdorn J, De Vlaminck K, Movahedi K, Räder HJ, Hernot S, Besenius P, Van Ginderachter JA, Nuhn L. Bolli E, et al. Adv Sci (Weinh). 2021 Mar 8;8(10):2004574. doi: 10.1002/advs.202004574. eCollection 2021 May. Adv Sci (Weinh). 2021. PMID: 34026453 Free PMC article. - Tumor-associated macrophages: unwitting accomplices in breast cancer malignancy.
Williams CB, Yeh ES, Soloff AC. Williams CB, et al. NPJ Breast Cancer. 2016;2:15025-. doi: 10.1038/npjbcancer.2015.25. Epub 2016 Jan 20. NPJ Breast Cancer. 2016. PMID: 26998515 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials